Liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus with stealth effect on the immune system
Abstract Oncolytic virotherapy has the disadvantage of being unsuitable for systemic delivery due to immune elimination. Liposomal encapsulation is well-recognized to reduce immune elimination and enhance the stability of drugs in the bloodstream. In the present study, the potential of liposome-enca...
Guardado en:
Autores principales: | Katsuyuki Aoyama, Shinji Kuroda, Toshiaki Morihiro, Nobuhiko Kanaya, Tetsushi Kubota, Yoshihiko Kakiuchi, Satoru Kikuchi, Masahiko Nishizaki, Shunsuke Kagawa, Hiroshi Tazawa, Toshiyoshi Fujiwara |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/20760a868f17433c8d8ecd81b0ee0a17 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma
por: Eonju Oh, et al.
Publicado: (2018) -
Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy
por: Huiya Huang, et al.
Publicado: (2019) -
Systemic therapy for cervical cancer with potentially regulatable oncolytic adenoviruses.
por: Anna Kanerva, et al.
Publicado: (2008) -
A potential bat adenovirus-based oncolytic virus targeting canine cancers
por: Hiromichi Matsugo, et al.
Publicado: (2021) -
Anti-tumor activity of a miR-199-dependent oncolytic adenovirus.
por: Elisa Callegari, et al.
Publicado: (2013)